Mild Cognitive Impairment (MCI)
Conditions
Interventions
placebo:placebo, oral, 12 months
folic acid:folic acid 0.8mg/day, oral, 12 months
DHA:DHA 800mg/day, oral, 12 months
folic acid+DHA:folic acid (0.8mg/day) + DHA (800mg/day), oral, 12 months
Sponsors
School of Public Health, Tianjin Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Community-based elderly subjects aged 60 years or older; 2. Memory complaints reported by the patient, family, or physician, of at least a 6-month duration and preferably corroborated by an informant; 3. Mild quantitative impairments in cognitive function were assessed by the Chinese version of the 30-point Mini Mental State Examination (MMSE) using age- and education-based norms (cutoff point was set at 1.5 SD below the mean age- and education-adjusted MMSE scores); 4. Decreased daily living ability and social function, as measured by the daily living scale, score is below 18; 5. Absence of dementia (according to DSM-IV criteria), psychiatric disorder, cerebral damage, or any active neuropsychiatric condition producing disability; Subjects conforming to five items above can be determined as MCI and included in our study.
Exclusion criteria
Exclusion criteria: 1. Neurological examination found the sign of local central nerve obstruction such as obvious paralysisunilateral sensory disturbance and aphasia etc, history of cerebrovascular diseases (hemorrhagic and ischemic stroke), brain injury or bone fracture; 2. Medical diseases such as asthmatic bronchitis, severe hypertension, angina pectoris and severe infection; 3. Psychotic patients with evident anxiety and depressed emotion and subjects with endocrine system history of disease(hyperthyroidism, thyroid hypofunction, systemic lupus eythematosus, rheumatoid arthritis); 4. Newly discovered or advanced tumor; 5. Visual perception,auditory perceptual disorders or languages communication difficulties, all of which may influence measurement of cognitive function; 6. Alcohol dependence and other psychoactive substance abuse such as antipsychotic drug,benzodiazepines or taking medicine influencing cognitive function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function (total intelligence quotient);Folate and methionine circulating metabolites;DHA;Luckocyte telomere length and damage;Inflammatory factors;Related gene expression; | — |
Countries
China
Contacts
Public ContactGuowei Hung
School of Public Health, Tianjin Medical University
Outcome results
None listed